

Anti-CCL21 Reference Antibody (Novartis patent anti-CCL21)

Catalog # APR11295

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	O00585
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-REM
Calculated MW	14646


Additional Information

Target/Specificity	CCL21
Expression system	CHO


Protein Information

Name	CCL21
Synonyms	SCYA21
Function	Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4 (PubMed: 23341447). Binds to chemokine receptor CCR7 (PubMed: 9507024). Does not bind to chemokine receptor CXCR3 (PubMed: 10201891). Binds to G protein-coupled receptor GPR174 (By similarity). Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs.
Cellular Location	Secreted.
Tissue Location	Highly expressed in high endothelial venules of lymph nodes, spleen and appendix. Intermediate levels found in small intestine, thyroid gland and trachea. Low level expression in thymus, bone marrow, liver, and pancreas. Also found in tonsil, fetal heart and fetal spleen


Images



anti-CCL21) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-CCL21 Reference Antibody (Novartis patent anti-CCL21) is 98.6%, determined by SEC-HPLC.



Immobilized hu-CCL21-his at 2 µg/mL can bind Novartis patent anti-CCL21, EC₅₀= 0.04345 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.